The effect of ribavirin on bone density in patients with chronic hepatitis C treated with interferon-ribavirin therapy

Journal of Pediatric Gastroenterology and Nutrition

Volumn 41, Issue 5, 2005, Pages 650-652

  Urganci, Nafiye ^a,b   Gulec, Seda Geylani ^a   Arapoglu, Mujde ^a   Vural, Sema ^a   Nuhoǧ, Asiye ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Cudi Efendi sok   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIFEDIOL; CALCIUM; CREATININE; MAGNESIUM; PARATHYROID HORMONE; PHOSPHORUS; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; AGE; ALOPECIA; ANOREXIA; ARTICLE; BONE DENSITY; BONE MINERAL; CHILDHOOD DISEASE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEVER; GENDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LUMBAR VERTEBRA; MALAISE; MALE; MINERAL METABOLISM; MYALGIA; PRIORITY JOURNAL; SCHOOL CHILD; SERUM;

ADOLESCENT; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LUMBAR VERTEBRAE; MALE; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 27644561483     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000182800.07794.01     Document Type: Article

References (15)

1. Hardikar W. Hepatitis C in childhood. J Gastroenterol Hepatol 2002;17:476-81.
2. Jonas MM. Children with hepatitis C. Hepatology 2002;36:173-8.
3. Di Marco V, Almasio P, Vaccaro A, et al. Combined treatment of relapse of chronic hepatitis C with high-dose α2b interferon plus ribavirin for 6 or 12 months. J Hepatol 2000;33:456-62.
4. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alpha-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis. Hepatology 2000;32:1131-7.
5. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
6. Bonkovsky HL, Stefancyk D, McNeal K, et al. Comparative effects of different doses of ribavirin plus interferon α-2b for therapy of chronic hepatitis. Dig Dis Sci 2001;46:2051-9.
7. Solis-Herruzo JA, Castellano G, Fernandez I, et al. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000;33:812-7.
8. Framarin L, Avataneo T, Salzedo E, et al. Vertebral osteopeni due to bone marrow hyperplasia during interferon-α and ribavirin therapy for chronic hepatitis C. Dig Liver Dis 2003;35:732-4.
9. Goldstein SR, Martino FP, Cort S. Ribavirin capsules (SCH 18908) investigator's brochure Schering-Plough research institute, 1997.
10. Trombetti A, Giostra E, Mentha G. Lack of evidence for ribavirin-induced bone loss. Hepatology 2002;36:255-57.
11. Moreira RO, Balduino A, Martins HSLH, et al. Ribavirin, but not interferon α-2b, is associated with impaired osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 2004;75:160.
12. Fonteles FJS, Paixao JBA, Coelho HSM, et al. Effects of ribavirin in combination with either interferon alpha or peginterferon alpha-2b on calcium and bone metabolism in patients with chronic hepatitis C. J Bone Miner Res 2002;17:336.
13. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of chronic hepatitis C. N Engl J Med 1998;339:1493-99.
14. Mc Hutchinson JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
15. Duarte MPC, Farias MLF, Coelho HSM, et al. Calcium-PTH-vitamin D axis and metabolic bone disease in chronic liver disease. J Gastroenterol Hepatol 2001;16:1022-27.